All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN PD-L1 < 1% PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - 2nd line (L2), pembrolizumab (10mg/kg) vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.74 [0.57; 0.96]
KEYNOTE-006 (3 week), 2015 0.69 [0.52; 0.91]
0.72 [0.59 ; 0.86 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 915 moderate not evaluable deaths (OS) (extension)detailed results KEYNOTE-006 (3 week), 2015 0.68 [0.53; 0.87]
0.68 [0.53 ; 0.87 ] KEYNOTE-006 (3 week), 2015 1 0% 555 NA not evaluable PFS (extension)detailed results KEYNOTE-006 (3 week), 2015 0.61 [0.50; 0.75]
0.61 [0.50 ; 0.75 ] KEYNOTE-006 (3 week), 2015 1 0% 555 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.50 [0.39; 0.64]
KEYNOTE-006 (3 week), 2015 0.58 [0.47; 0.72]
0.54 [0.46 ; 0.64 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 915 moderate not evaluable objective responses (ORR)detailed results KEYNOTE-002 (10 mg/kg), 2015 8.16 [3.74; 17.80]
KEYNOTE-006 (3 week), 2015 3.63 [2.34; 5.65]
5.09 [2.33 ; 11.13 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 68% 915 moderate not evaluable STRAE (any grade)detailed results KEYNOTE-006 (3 week), 2015 0.63 [0.39; 1.03]
0.63 [0.39 ; 1.03 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable STRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable TRAE (any grade)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.76 [0.45; 1.26]
KEYNOTE-006 (3 week), 2015 1.16 [0.78; 1.72]
0.97 [0.64 ; 1.46 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 40% 883 moderate not evaluable TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.54 [0.32; 0.91]
KEYNOTE-006 (3 week), 2015 0.82 [0.53; 1.28]
0.68 [0.46 ; 1.02 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 29% 883 moderate not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.40 [0.11 ; 18.31 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.65 [0.70; 3.87]
KEYNOTE-006 (3 week), 2015 1.23 [0.69; 2.18]
1.35 [0.84 ; 2.17 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 2.73 [0.85; 8.76]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
2.50 [0.82 ; 7.64 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Abdominal pain TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.06 ; 15.07 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.05 [0.00; 0.88]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.13 [0.01 ; 1.12 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.10 ; 9.13 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39]
KEYNOTE-006 (3 week), 2015 0.23 [0.01; 5.12]
0.51 [0.06 ; 4.02 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Chills TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 2.90 [0.30; 28.13]
KEYNOTE-006 (3 week), 2015 0.34 [0.14; 0.83]
0.76 [0.10 ; 5.79 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 66% 883 moderate not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.06 ; 15.07 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.06 ; 15.07 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 1.85 [0.06; 55.43]
1.85 [0.06 ; 55.43 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.28 [0.28; 5.81]
KEYNOTE-006 (3 week), 2015 0.39 [0.10; 1.52]
0.67 [0.21 ; 2.15 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 24% 883 moderate not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.06 ; 15.07 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
0.92 [0.06 ; 14.85 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.05; 1.10]
KEYNOTE-006 (3 week), 2015 0.92 [0.18; 4.62]
0.45 [0.12 ; 1.77 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 32% 883 moderate not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 3.85 [0.17; 86.06]
KEYNOTE-006 (3 week), 2015 4.69 [0.54; 40.40]
4.40 [0.75 ; 25.82 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.63 [0.05 ; 8.23 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
0.56 [0.07 ; 4.37 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.06 ; 15.07 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
0.46 [0.04 ; 5.11 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
0.46 [0.04 ; 5.11 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.07 [0.00; 1.17]
0.07 [0.00 ; 1.17 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.24 [0.14 ; 10.63 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.48 [0.02; 14.29]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.47 [0.04 ; 5.19 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.33 [0.05 ; 2.22 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.02 ; 13.80 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.08 [0.00; 1.39]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.18 [0.02 ; 1.90 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
1.92 [0.06 ; 57.48 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.63 [0.05 ; 8.23 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.24 [0.01; 5.29]
0.24 [0.01 ; 5.29 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 5.81 [0.29; 116.90]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
2.16 [0.28 ; 16.57 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.06 ; 15.07 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.06 ; 15.07 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12]
0.23 [0.03 ; 2.12 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.40 [0.11 ; 18.31 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Vitiligo TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
0.96 [0.02 ; 48.41 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.33 [0.05 ; 2.22 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015 2 0% 883 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.02 ; 13.80 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 02:47 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 286,69,129
- treatments: 575